1. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.
- Author
-
Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, and Hohlfeld R
- Subjects
- Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Azathioprine pharmacology, Azathioprine therapeutic use, Europe, Glatiramer Acetate, Humans, Immunoglobulins, Intravenous pharmacology, Immunoglobulins, Intravenous therapeutic use, Immunologic Factors administration & dosage, Interferon-beta pharmacology, Interferon-beta therapeutic use, Magnetic Resonance Imaging, Mitoxantrone pharmacology, Mitoxantrone therapeutic use, Multiple Sclerosis diagnosis, Natalizumab, Peptides pharmacology, Peptides therapeutic use, Plasmapheresis, Randomized Controlled Trials as Topic, Societies standards, Health Planning Guidelines, Immunologic Factors therapeutic use, Multiple Sclerosis therapy
- Abstract
This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature has been extracted for new evidence from randomized controlled trials, open treatment studies and reported expert opinion, both in original articles and reviews, and evaluates indications and safety issues based on published data. After data extraction from published full length publications and critically weighing the evidence and potential impact of the data, the review has been drafted and circulated within the National MS Societies and the European MS Platform to reach consensus within a very large group of European experts, combining evidence-based criteria and expert opinion where evidence is still incomplete. The review also outlines a few areas of controversy and delineates the need for future research.
- Published
- 2008
- Full Text
- View/download PDF